BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT. The fireside chat will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be a ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2023 Earnings Conference Call March 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy & Investor Relations Jurgi Camblong - Co-Founder & Chief Executive Officer Ross Muken - Chief Executive Officer & Chief Operating Officer Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Conor McNamara - RBC Capital Markets Operator Good morning. My name is Drew, and I will be your conference operator today. At this time, I would like ...

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue grew 27% year-over-year to $17.0 million; Constant currency revenue excluding COVID-related revenue also grew 27% year-over-yearGross margins were 70% on a reported basis and 73% on an adjusted basis ...

Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2023 SOPHiA GENETICS SA Rolle Report of the statutory auditor to the General Meeting on the consolidated financial statements 2023 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Rolle Report on the audit of the consolidated financial statements Opinion We have audited the consolidated financial statements of SOPHiA GENETICS SA and its subsidiaries (the Group), which comprise the consolidated ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (For the fiscal year ended December 31, 2023) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be we ...

BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be we ...

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZ ...

The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities BOSTON and ROLLE, Switzerland, Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine to the Brazilian population, is now live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETI ...

RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON and ROLLE, Switzerland, Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its  Precision Biology Services portfolio. RareCyte is an innovative precision bi ...